170377 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates; Assays involving proteins of known structure or function as defined in the subgroups; Details Complement proteins, e.g. anaphylatoxin, C3a, C5a
COMPLEMENT PROTEIN C8 GAMMA BIOMARKERS FOR DETECTING AND MONITORING CANCERS
#2COMPLEMENT C4D ASSAY
#3BIOMARKERS
#4TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR
#5New C5a Binding Nucleic Acids
#6Use of reagent for detecting C1QBP protein expression level in preparation for oral cancer screening or prognosis kit
#7INHIBITORS OF COMPLEMENT FACTOR H
#8COMPLEMENT-DEPENDENT CYTOTOXICITY METHODS
#9ANTI-C3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
#10Methods for Sample Quality Assessment
#11METHODS FOR DETECTING CM-TMA BIOMARKERS
#12COMBINATION OF BIOMARKERS, AND METHOD FOR DETECTING COGNITIVE DYSFUNCTION OR RISK THEREOF BY USING SAID COMBINATION
#13ORAL MESENCHYMAL STEM CELLS AND USE THEREOF
#14METHODS FOR IMPROVING LUNG TRANSPLANTS
#15BIOMARKERS OF HIDDEN OBESITY FOR USE IN PREVENTATIVE HEALTHCARE
#16ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOF
#17BIOMARKER FOR DIAGNOSING CANCER AND USE THEREOF
#18BIOMARKER FOR CANCER DIAGNOSIS AND USE THEREOF
#19C5a binding nucleic acids
#20METHOD FOR DETERMINING THE BINDING OF AN ANTIBODY TO THE COMPLEMENT COMPONENT IQ (CIQ)
#21ASSAY METHODS FOR SCREENING INHIBITORS OF SICKLE CELL DISEASE, ß-THALASSEMIA, OR SICKLE CELL ß-THALASSEMIA, OR A PHENOTYPE THEREOF
#22Inhibitors of complement factor H
#23DIAGNOSTIC BIOMARKER FOR CANCER AND USE THEREOF
#24Artificial Intelligence Systems and Processes for In Silico Discovery of Immune Modulators and T Regulatory Cell Screening Methodologies
#25IMMUNOLOGICAL ASSAY METHOD
#26TARGET MEASUREMENT
#27SCREENING FOR THE EFFECTS OF COMPLEMENT PROTEIN CHANGES
#28THERAPEUTIC OLIGONUCLEOTIDES
#29METHODS AND KITS FOR DIAGNOSING SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES
#30METHOD FOR PROGNOSIS AND TREATING A PATIENT SUFFERING FROM CANCER
#31INHIBITORY NUCLEIC ACIDS FOR FACTOR H FAMILY PROTEINS
#32ELISA Assay for Measuring Function of Properdin and Kits for Conducting ELISA Assays using Anti-properdin Antibodies
#33Properdin binding protein and use thereof
#34METHOD OF DETERMINING PROGNOSIS OF CHRONIC KIDNEY DISEASE
#35Targeted delivery system and methods of use therefor
#36METHOD FOR PROGNOSIS AND TREATING A PATIENT SUFFERING FROM CANCER
#37ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
#38ANTI-C5 ANTIBODIES AND METHODS OF USE
#39METHODS OF TREATING, DIAGNOSING AND PREDICTING PROGNOSIS OF SEPSIS
#40COMPOSITIONS AND METHODS FOR TREATING EPILEPSY
#41HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
#42METHODS OF ASSESSING RISK OF AND TREATING PREECLAMPSIA AND SUBTYPES THEREOF
#43BINDING PROTEINS FOR COMPLEMENT FACTOR H (CFH)
#44COMPOSITIONS, METHODS AND KITS FOR TREATING COMPLEMENT RELATED DISORDERS
#45DETECTION OF COMPLEMENT PROTEINS
#46METHOD FOR DETERMINING THE FREE ANTIGEN OF AN ANTIBODY IN A SAMPLE
#47COMPLEMENTOME ASSAY
#48Methods for Determining a Level of Cell-Bound Complement Activation Product
#49METHOD OF USING EXTRACELLULAR VESICLES TO DETECT COMPLEMENT ACTIVATION, AND USES THEREOF TO ASSESS AND/OR MONITOR TREATMENT OF A COMPLEMENT-MEDIATED DISEASE
#50METHOD FOR TREATING COMPLEMENT MEDIATED DISORDERS CAUSED BY BETACORONAVIRUSES
#51METHODS AND SYSTEMS OF PROTEOME ANALYSIS AND IMAGING
#52METHOD FOR MEASURING THE PROTEASE ACTIVITY OF C3 AND C5 CONVERTASE OF THE ALTERNATIVE COMPLEMENT PATHWAY
#53ANTI-C3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
#54ISOLATED ANTIGEN BINDING PROTEIN AND USE THEREOF
#55A METHOD OF DIAGNOSING AND/OR PROGNOSING PREECLAMPSIA
#56METHODS AND DEVICES FOR DETERMINING A LEVEL OF A COMPLEMENT ACTIVATION PRODUCT
#57BIOMARKERS FOR DIAGNOSING BREAST CANCER AND USES THEREOF
#58COMPANION DIAGNOSIS BIOMARKER COMPOSITION AND COMPANION DIAGNOSIS KIT CONTAINING SAME
#59COMPANION DIAGNOSTICS FOR COMPLEMENT INHIBITORS
#60Assay for Assessing Heart Failure
#61EXOSOME ASSAY FOR DEPRESSION AND PSYCHOSIS AND METHODS AND AGENTS FOR TREATING DEPRESSION, PSYCHOSIS AND SCHIZOPHRENIA
#62THERAPEUTIC OLIGONUCLEOTIDES
#63METHODS FOR TARGETED ASSESSMENT AND TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ACUTE EVENTS AND MORTALITY ASSOCIATED THEREWITH
#64Methods of inhibiting complement factor H (CFH) comprising administering an antibody that binds CFH
#65Atypical hemolytic uremic syndrome (AHUS) biomarker proteins
#66Anti-complement factor C1Q antibodies and uses thereof
#67COMPLEMENT C4D ASSAY
#68ANTIBODY MOLECULES TO COMPLEMENT COMPONENT 5 AND USES THEREOF
#69METHODS FOR DIAGNOSING, PROGNOSING AND MONITORING TREATMENT FOR THROMBOSIS IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
#70COMPLEMENT ALTERNATIVE PATHWAY-ASSOCIATED NEPHROPATHY BIOMARKERS
#71Methods of detecting donor-specific antibodies and systems for practicing the same
#72Cell-penetrating compstatin analogs and uses thereof
#73Targeted delivery system and methods of use therefor
#74C5a binding nucleic acids
#75A THREE-PROTEIN PROTEOMIC BIOMARKER FOR PROSPECTIVE DETERMINATION OF RISK FOR DEVELOPMENT OF ACTIVE TUBERCULOSIS
#76Compositions, methods and kits for treating complement related disorders
#77Disease detection method
#78HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
#79Means and methods for determining risk of type-1 diabetes by serum protein biomarkers
#80High throughput method for measuring the protease activity of complement C3 convertase
#81A METHOD FOR DIAGNOSING METABOLIC DISORDER
#82Biomarkers for Typing Allograft Recipients
#83Detection of high risk drusen
#84TREATMENT OF DISORDERS
#85ASTROCYTE EXOSOME COMPLEMENT-BASED ASSAY FOR NEUROINFLAMMATION IN ALZHEIMER'S DISEASE AND USES THEREOF
#86Anti-complement factor C1q Fab fragments and uses thereof
#87Therapeutic oligonucleotides
#88Anti-complement factor C1Q antibodies and uses thereof
#89COMPOSITIONS AND METHODS FOR TREATING CANCER
#90Compositions and methods for regulating pancreatic beta cell function using adipsin
#91Method of detecting the presence of complement C5
#92System and method for detection of trauma
#93Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure
#94ELISA assay for measuring function of properdin and kits for conducting ELISA assays using anti-properdin antibodies
#95HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
#96Anti-complement factor H antibodies
#97Methods for detection, staging, and surveillance of colorectal adenomas and carcinomas
#98Method of quantitating unbound C5 in a sample
#99Cell-penetrating compstatin analogs and uses thereof
#100Methods of diagnosing endometriosis
#101Anti-complement factor C1q antibodies and uses thereof
#102COMPOSITIONS AND METHODS RELATING TO C5L2
#103Method of measuring cell-substrate impedance in living cells to identify compounds affecting receptor tyrosine kinase (RTK) activity and pathways for the treatment of cancer
#104Qualitative predictive method for differential diagnosis of pneumococcal, meningococcal and viral meningitis, method and kit for differential diagnosis of meningitis
#105COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY
#106Method for Identifying an Agent for Treating Abnormal Kidney Function
#107Proteins with diagnostic and therapeutic uses
#108Methods of detecting donor-specific antibodies and systems for practicing the same
#109Nucleic acids encoding anti-C5 antibodies
#110METHODS AND COMPOSITIONS FOR DETECTING AND TREATING SCHIZOPHRENIA
#111SEMAPHORIN 3A FOR TREATMENT AND PROGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
#112BIOMARKERS FOR DETECTION OF TUBERCULOSIS RISK
#113Diagnostics and Therapeutics for Macular Degeneration-Related Disorders
#114Methods and systems of proteome analysis and imaging
#115Complement split product C4d for the treatment of inflammatory conditions
#116Dried cellulose-treated tissue for in-vitro complement activation assays and diagnostic kits
#117Targeted delivery system and methods of use therefor
#118INHIBITION OF THE COMPLEMENT SYSTEM
#119C5a binding nucleic acids
#120Cardiovascular risk event prediction and uses thereof
#121Therapeutic oligonucleotides
#122METHOD OF INHIBITING C5 CLEAVAGE
#123PROTEIN BIOMARKER PANELS FOR DETECTING COLORECTAL CANCER AND ADVANCED ADENOMA
#124METHOD AND KIT FOR EXAMINING COMPLEMENT SYSTEM
#125ASSAY AND METHOD FOR DETERMINING CDC ELICITING ANTIBODIES
#126Methods of neutralizing C5 with anti-C5 antibodies
#127Method of measuring cell-substrate impedance in living cells to identify compounds affecting receptor tyrosine kinase (RTK) activity and pathways
#128Anti-complement factor C1q antibodies and uses thereof
#129Method for measuring anti-drug antibody
#130Method for identifying an agent for treating abnormal kidney function
#131COMPLIMENT FACTOR I BIOASSAY
#132ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) BIOMARKER PROTEINS
#133Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways
#134Methods and compositions for diagnosis and treatment of meningitis
#135ANTISECRETORY FACTOR COMPLEX ASSAY
#136Compositions, methods and kits for treating complement related disorders
#137Methods of treating or preventing periodontitis and diseases associated with periodontitis
#138Method for the diagnosis of or risk for a disease mediated via the alternative pathway of the complement system
#139Means and methods for determining risk of type-1 diabetes by serum protein biomarkers
#140Methods for detecting an amount of complement factor B protein and carbohydrate antigen 19-9 protein, and methods for diagnosing and treating pancreatic cancer using the same
#141Anti-complement factor C1q Fab fragments and uses thereof
#142Methods of measuring factor D activity and potency of factor D inhibitors
#143Methods and compositions for diagnosis and treatment of meningitis
#144C1q-ADIPONECTIN COMPLEX AND USE THEREOF
#145Compositions and methods for regulating pancreatic beta cell function using adipsin
#146Cell-bound complement activation products as diagnostic biomarkers for pre-lupus
#147Modulation of synaptic maintenance
#148Protein biomarkers for immune assessment and prediction of transplant rejection
#149Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs
#150Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
#151Qualitative predictive method for differential diagnosis of pneumococcal meningococcal and viral meningitis, method and kit for differential diagnosis of meningitis
#152Anti-complement factor C1q antibodies and uses thereof
#153Non-Invasive Biomarker of Antibody-Mediated Allograft Rejection
#154Humanized anti-complement factor C1Q antibodies
#155Modulation of synaptic maintenance
#156Anti-Complement factor H antibodies
#157Bladder carcinoma biomarkers
#158COMPOSITIONS AND METHODS RELATING TO C5L2
#159Proteins with diagnostic and therapeutic uses
#160Kidney disease biomarker
#161Cell-penetrating compstatin analogs and uses thereof
#162Methods of treatment of HSCT-associated thrombotic microangiopathy with eculizumab
#163Modulation of synaptic maintenance
#164Anti-C5 antibodies
#165Atypical hemolytic uremic syndrome (AHUS) biomarker proteins
#166COMPLEMENT ASSAYS AND USES THEREOF
#167Treating cancer deficient in FANCA, FANCD2, FANCE, or FANCG with an ATM inhibitor
#168NOVEL ASSAY
#169Semaphorin 3A for treatment of systemic lupus erythematosus
#170METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE
#171Method of inhibiting C5 cleavage
#172DETECTING COMPLEMENT ACTIVATION
#173Methods of detecting donor-specific antibodies and systems for practicing the same
#174METHODS OF DIAGNOSING ENDOMETRIOSIS
#175Marker for diagnosing diabetic retinopathy and use thereof
#176Method and biomarkers for the detection of dengue hemorrhagic fever
#177Modulation of synaptic maintenance
#178Modulation of synaptic maintenance
#179Modulation of synaptic maintenance
#180INHIBITION OF THE COMPLEMENT SYSTEM
#181Method of assessing a subject for abnormal kidney function
#182Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders
#183METHOD AND SYSTEM FOR DIAGNOSING AND TREATING PREECLAMPSIA
#184Method for the detection of an albumin isoform
#185SCREENING ASSAYS FOR COMPLEMENT COMPONENT C5 ANTAGONISTS
#186therapeutic based on CMP-nonulosonate sugars
#187Complement split product C4d for the treatment of inflammatory conditions
#188Dynamic monitoring of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) activity and pathways in living cells using real-time microelectronic cell sensing technology
#189Neo antibodies for diagnostic imaging of tissue injury
#190Method for evaluating ischemic heart disease by assaying complement factor H or D
#191BIOMARKERS FOR BREAST CANCER
#192Lung cancer molecular markers
#193Detecting complement activation
#194C1q-ADIPONECTIN COMPLEX AND USE THEREOF
#195Method for species-independent measurement of complement activation in animals
#196C5a binding nucleic acids
#197Method of assessing diabetic nephropathy using CD5 antigen-like
#198Neoantibodies for diagnosing tissue injury
#199Methods of treating or preventing periodontitis and diseases associated with periodontitis
#200Systems and methods for medical data processing and analysis
#201Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
#202Method for measuring IgG-mediated complement activation
#203Evaluation method for arteriosclerosis
#204Alternative pathway specific antibodies for treating arthritis
#205METHODS OF DIAGNOSING ENDOMETRIOSIS
#206Methods and biomarkers for the detection of dengue hemorrhagic fever
#207Modulation of synaptic maintenance
#208Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways
#209Detecting complement activation
#210Dynamic monitoring of activation of receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology
#211METHODS AND COMPOSITIONS FOR TARGETING GC1QR/P32
#212Modulation of synaptic maintenance
#213Cancer biomarker and the use thereof
#214SERUM BIOMARKERS FOR CHAGAS DISEASE
#215Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders
#216Complement assays and uses thereof
#217Ficolin-3 assay
#218Variants in complement regulatory genes predict age-related macular degeneration
#219Serum Biomarkers For Early Detection Of Acute Cellular Rejection
#220METHODS AND COMPOSITIONS FOR THE REGULATION OF LECTIN COMPLEMENT PATHWAY (LCP)-ASSOCIATED COMPLEMENT ACTIVATION IN HYPERGLYCEMIC MYOCARDIAL DAMAGE
#221Methods and compositions for detection of complement fixing antibodies
#222DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING COMPLEMENT COMPONENTS ON WHITE BLOOD CELLS
#223Complement inhibitors
#224Diagnostics and Therapeutics for Macular Degeneration-Related Disorders
#225Methods of diagnosing endometriosis
#226Sample hepatocarcinoma classification with YKL-40 to MASP2 concentration ratio
#227Complement-mediated thrombophilic assay
#228Compositions and methods for modulating the activity of complement regulatory proteins on target cells
#229Complement factor H-based assays for serum bactericidal activity against
#230METHOD FOR DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES
#231Compositions and Methods for Detecting and Quantifying Toxic Substances in Disease States
#232C5 Antigens and Uses Thereof
#233Isoform specificities of blood serum proteins and their use as differentially expressed protein biomarkers for diagnosis of breast cancer
#234Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
#235Identities, specificities, and use of twenty two (22) differentially expressed protein biomarkers for blood based diagnosis of breast cancer
#236C4d/C4b standard for quantitative flow cytometry of humoral transplant rejection
#237DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING COMPLEMENT COMPONENTS ON WHITE BLOOD CELLS
#238Blood C5a Levels as an Indicator of Rhinoconjunctivitis Severity
#239Diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases
#240Compositions and methods of treating cancer
#241Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer
#242Method to Determine Pseudo-Allergic Reactions
#243Membrane Attack Complexes Associated with Circulating Immune Complexes
#244Methods of diagnosing endometriosis
#245Variants in complement regulatory genes predict age-related macular degeneration
#246Screening assays for binding antagonists of the AMD-associated variant of factor H (H384)
#247Determination of risk of developing dengue hemorrhagic fever/dengue shock syndrome, methods and compositions therefor
#248COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
#249Methods and compositions for targeting gC1qR/p32
#250Complement inhibitors
#251Modulation of synaptic maintenance
#252Diagnosing and monitoring inflammatory diseases by measuring complement components on white blood cells
#253Diagnostics and therapeutics for macular degeneration-related disorders
#254Transgenic mice containing anaphylatoxin C3a gene disruptions
#255Receptor and screening methods
#256Plasma C5A levels as an indicator of asthma severity
#257Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
#258Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology
#259Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology
#260Real time method of detecting acute inflammatory conditions
#261Method and kit for donor specific complement-fixing antibodies crossmatch
#262Serum biomarkers for Chagas disease
#263Heteropolymer complexes and methods for their use
#264Using complement component C1q derived molecules as tracers for fluorescence polarization assays
#265Monitoring immunologic, hematologic and inflammatory diseases
#266C1q complement inhibitors and methods of use thereof